Aquestive Therapeutics Inc (AQST)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
AQST
Aquestive Therapeutics Inc
$4.25
0.00%
HEALTHCARE · Cap: $469.25M
TAK
Takeda Pharmaceutical Co Ltd ADR
$17.63
+1.38%
HEALTHCARE · Cap: $55.82B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 9187970% more annual revenue ($4.62T vs $50.27M). TAK leads profitability with a -3.5% profit margin vs -137.1%. TAK earns a higher WallStSmart Score of 53/100 (C-).
AQST
Avoid28
out of 100
Grade: F
TAK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.2%
Fair Value
$2.56
Current Price
$4.25
$1.69 premium
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 65.7% year-over-year
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Generating 73.8B in free cash flow
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Weak financial health signals
ROE of 2.4% — below average capital efficiency
Earnings declined 9.8%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AQST
The strongest argument for AQST centers on Revenue Growth, Debt/Equity. Revenue growth of 65.7% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : AQST
The primary concerns for AQST are EPS Growth, Market Cap, Return on Equity.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
AQST profiles as a hypergrowth stock while TAK is a turnaround play — different risk/reward profiles.
AQST carries more volatility with a beta of 1.43 — expect wider price swings.
AQST is growing revenue faster at 65.7% — sustainability is the question.
TAK generates stronger free cash flow (73.8B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (53/100 vs 28/100) and 10.2% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aquestive Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?